ABRAXANE® Extends Survival By Nearly Two Months For Patients With Advanced Pancreatic Cancer
MANHATTAN BEACH, Calif., Jan. 22, 2013 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce that today Celgene Corporation (Celgene) reported that the combination of its chemotherapeutic drug ABRAXANE® with gemcitabine improved overall survival in patients with metastatic pancreatic cancer by nearly two months (8.5 months vs. 6.7 months) when compared with gemcitabine alone. According to Celgene, this combination also demonstrated a 59 percent increase in one-year survival compared to patients receiving gemcitabine alone.
"The positive results of this trial indicate another step forward in the treatment of this insidious disease where historically few effective treatment options have existed. This success also illustrates that clinical trials can give pancreatic cancer patients access to state-of-the art treatments that may be their best option. We are pleased that patients will have another choice when making treatment decisions," stated Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. "Further, this positive news brings us one step closer to doubling the survival rate of pancreatic cancer by 2020."
The phase III study included 861 metastatic pancreatic cancer patients from around the world. Celgene plans to submit their findings to the FDA for approval of ABRAXANE in pancreatic cancer. ABRAXANE was previously approved for breast cancer in 2005 and in October 2012 was approved for a type of lung cancer. It is a form of the chemotherapy drug paclitaxel that is modified by the addition of a human protein called albumin.The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. The organization has a comprehensive up-to-date database of all approved pancreatic cancer-specific clinical trials taking place nationwide and can do a customized eligibility search for patients through our Patient and Liaison Services program.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts